Table 1 Baseline characteristics of all participants by RLP-C quartile
Variables | Total | RLP-C, mmol/L | P Value | |||
|---|---|---|---|---|---|---|
Q1 (< 0.39) | Q2 (0.39–< 0.54) | Q3 (0.54–< 0.73) | Q4 (≥0.73) | |||
n | 5173 | 1269 | 1283 | 1318 | 1303 | Â |
Age, y | 55.0 ± 8.5 | 54.2 ± 8.8 | 55.3 ± 9.1 | 55.5 ± 8.2 | 55.0 ± 7.9 | < 0.001 |
Male, n (%) | 1845 (35.7%) | 365 (28.8%) | 444 (34.6%) | 476 (36.1%) | 560 (43.0%) | < 0.001 |
BMI, kg/m2 | 25.5 ± 3.3 | 24.0 ± 3.0 | 25.3 ± 3.2 | 26.1 ± 3.2 | 26.7 ± 3.1 | < 0.001 |
eGFR, mL/min·1.73m2 | 96.8 ± 12.0 | 98.7 ± 11.4 | 96.9 ± 11.9 | 96.1 ± 11.9 | 95.4 ± 12.5 | < 0.001 |
cSBP, mmHg | 129.7 ± 17.3 | 126.1 ± 16.8 | 129.0 ± 17.3 | 130.2 ± 16.8 | 133.2 ± 17.4 | < 0.001 |
TC, mmol/L | 5.4 ± 1.0 | 4.8 ± 0.8 | 5.1 ± 0.8 | 5.5 ± 0.9 | 6.0 ± 1.1 | < 0.001 |
TG, mmol/L | 1.2 (0.9–1.8) | 0.8 (0.6–0.9) | 1.1 (0.9–1.3) | 1.4 (1.2–1.7) | 2.3 (1.8–3.1) | < 0.001 |
HDL-C, mmol/L | 1.5 ± 0.4 | 1.8 ± 0.4 | 1.5 ± 0.3 | 1.4 ± 0.3 | 1.2 ± 0.3 | < 0.001 |
LDL-C, mmol/L | 3.3 ± 0.8 | 2.7 ± 0.6 | 3.2 ± 0.6 | 3.5 ± 0.7 | 3.7 ± 1.0 | < 0.001 |
RLP-C, mmol/L | 0.5 (0.4–0.7) | 0.3 (0.2–0.4) | 0.5 (0.4–0.5) | 0.6 (0.6–0.7) | 0.9 (0.8–1.1) | < 0.001 |
Non-HDL-C, mmol/L | 3.9 ± 1.0 | 3.0 ± 0.6 | 3.6 ± 0.6 | 4.1 ± 0.7 | 4.8 ± 1.0 | < 0.001 |
Smoking, n (%) | 1038 (20.1%) | 163 (12.8%) | 219 (17.1%) | 275 (20.9%) | 381 (29.2%) | < 0.001 |
Drinking, n (%) | 1255 (24.3%) | 250 (19.7%) | 299 (23.3%) | 317 (24.1%) | 389 (29.9%) | < 0.001 |
Prevalence of cardiovascular disease, n (%) | ||||||
 Diabetes mellitus | 953 (18.4%) | 159 (12.5%) | 208 (16.2%) | 253 (19.2%) | 333 (25.6%) | < 0.001 |
 Self-reported Myocardial Infarction | 21 (0.4%) | 0 (0.0%) | 7 (0.6%) | 7(0.5%) | 7 (0.5%) | 0.077 |
 Self-reported Stroke history | 97 (1.9%) | 21 (1.7%) | 30 (2.3%) | 28 (2.1%) | 18 (1.4%) | 0.261 |
 Hypertension | 1342 (25.9%) | 237 (18.7%) | 311 (24.2%) | 355 (26.9%) | 439 (33.7%) | < 0.001 |
 Antidiabetic medication use | 325 (6.3%) | 60 (4.7%) | 76 (5.9%) | 88 (6.7%) | 101 (7.8%) | 0.013 |